Please login to the form below

Not currently logged in
Email:
Password:

Zealand adds two observers to board of directors

Martin Nicklasson and Catherine Moukheibir join the firm
Martin Nicklasson

Denmark-based pharma company Zealand Pharma has added Dr Martin Nicklasson and Catherine Moukheibir the company's board of directors in the role of observers.

The announcement comes just days after the pharma company revealed Britt Meelby Jensen as its new CEO.

Nicklasson has held various executive VP positions at AstraZeneca and was president and CEO of BioVitrum and Swedish Orphan Biovitrum. He is also chairman of the board of Basilea, Orexo and Farma Holding.

Catherine Moukheibir has held senior management positions in several European biotech companies after an initial career in strategy consulting and investment banking. She is currently a non-executive board member of Creabilis and Ablynx.

Daniel Ellens, chairman of the Zealand board of directors, said: “They provide important and broad-based experience from public life science companies and are important additions to the competences on the board as we prepare for the next steps in Zealand's growth strategy as a maturing biotech company.”

12th November 2014

From: Research, Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics